# Gavestinel sodium salt

**Cat. No.:** HY-107700

**CAS No.:** 153436-38-5

**Molecular Formula:** $C_{18}H_{11}Cl_2N_2NaO_3$

**Molecular Weight:** 397.19

**Target:** iGluR

**Pathway:** Membrane Transporter/Ion Channel; Neuronal Signaling

**Storage:** 4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)




## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 100 mg/mL (251.77 mM; Need ultrasonic)

**Preparing Stock Solutions**

| Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.5177 mL | 12.5884 mL | 25.1769 mL |
| 5 mM | 0.5035 mL | 2.5177 mL | 5.0354 mL |
| 10 mM | 0.2518 mL | 1.2588 mL | 2.5177 mL |

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (6.29 mM); Clear solution

## BIOLOGICAL ACTIVITY

**Description**

Gavestinel (GV 150526A) is a potent, selective, orally active and non-competitive antagonist of NMDA receptor. Gavestinel binds to the glycine site of the NMDA receptor, with a $pK_i$ of 8.5. Gavestinel can be used for the research of acute ischemic stroke[1].

**$IC_{50}$ & Target**

NMDA Receptor

## REFERENCES

[1]. Fabio RD, et, al. Substituted indole-2-carboxylates as in vivo potent antagonists acting as the strychnine-insensitive glycine binding site. J Med Chem. 1997 Mar 14;40(6):841-50.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA